160 episodes

This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.

Xtalks Life Science Podcast Xtalks

    • Science
    • 5.0 • 3 Ratings

This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.

    Gene Editing Innovations with Programmable Gene Insertion (PGI) Technology ft. Dr. John Finn, Tome Biosciences

    Gene Editing Innovations with Programmable Gene Insertion (PGI) Technology ft. Dr. John Finn, Tome Biosciences

    In this episode, Ayesha spoke with John Finn, PhD, Chief Scientific Officer at Tome Biosciences, a company developing programmable gene insertion (PGI) technology.PGI is a cutting-edge gene editing technology that allows for the insertion of large sequences of DNA with site-specific precision. PGI is a revolutionary approach for the development of potentially curative cell and integrative gene therapies. The technology underlies Tome’s investigational candidate therapeutics for autoimmune dis...

    • 33 min
    New Frontiers in Epilepsy and Seizure Treatments ft. Dr. Jeremy Levin and Meg Alexander, Ovid Therapeutics

    New Frontiers in Epilepsy and Seizure Treatments ft. Dr. Jeremy Levin and Meg Alexander, Ovid Therapeutics

    In this episode, Ayesha spoke with Jeremy Levin, D. Phil, MB BChir, CEO and Chairman of Ovid Therapeutics Inc., and Meg Alexander, Chief Strategy Officer at Ovid.Ovid Therapeutics is a biopharmaceutical company focused on the development of medicines for epilepsies and seizure-related neurological disorders.Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries and a member of the executive committee at Bristol-Myers Squibb (BMS) Company where he was the arc...

    • 47 min
    The State of Infectious Diseases and New Trivalent Flu Vaccine ft. Infectious Disease Experts Dr. William Schaffner and Dr. Kelly Moore

    The State of Infectious Diseases and New Trivalent Flu Vaccine ft. Infectious Disease Experts Dr. William Schaffner and Dr. Kelly Moore

    In this episode, Ayesha spoke with William Schaffner, MD, Professor of Preventive Medicine Health Policy and Professor in the Division of Infectious Diseases at Vanderbilt University; and Kelly Moore, MD, MPH, President and CEO at Immunize.org and Associate Professor of Health Policy at Vanderbilt University.Dr. Schaffner and Dr. Moore discussed the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommendation of a trivalent influenza vaccine strain selection, as o...

    • 48 min
    Psychedelic-Based Therapeutics for Generalized Anxiety Disorder (GAD) – Interview with Robert Barrow, CEO, MindMed

    Psychedelic-Based Therapeutics for Generalized Anxiety Disorder (GAD) – Interview with Robert Barrow, CEO, MindMed

    In this episode, Ayesha spoke with Robert Barrow, CEO and Board Director at MindMed, a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The company is developing innovative psychedelic-based product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a ...

    • 26 min
    Developing Conditionally Active Antibodies: Interview with John K. Celebi, President & CEO, Sensei Bio.

    Developing Conditionally Active Antibodies: Interview with John K. Celebi, President & CEO, Sensei Bio.

    In this episode, Ayesha spoke with John K. Celebi, MBA, President & Chief Executive Officer, Sensei Bio, a clinical-stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients.Sensei Biotherapeutics specializes in creating conditionally active antibodies. These are engineered to operate specifically within the tumor microenvironment, enhancing the immune system's ability to combat cancer.John Celebi, MBA, has over 25 years of ...

    • 28 min
    Treg Cell Therapy for Neurodegenerative Diseases – Interview with Dr. Howard Berman, CEO, Coya Therapeutics

    Treg Cell Therapy for Neurodegenerative Diseases – Interview with Dr. Howard Berman, CEO, Coya Therapeutics

    In this episode, Ayesha spoke with Howard Berman, PhD, Founder and CEO of Coya Therapeutics, a clinical-stage biotech company developing regulatory T cell (Treg) therapies targeting neurodegenerative, autoimmune and metabolic diseases. Dr. Berman founded Coya Therapeutics in 2021. Dr. Berman has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibi...

    • 34 min

Customer Reviews

5.0 out of 5
3 Ratings

3 Ratings

Phoeptar ,

Great show, great hosts

This is now added to the other science and technology shows I listen to weekly. The hosts make it, their chemistry and individual knowledge base they bring to the discussions make it very enjoyable.

Top Podcasts In Science

Science Vs
Spotify Studios
Hidden Brain
Hidden Brain, Shankar Vedantam
Ologies with Alie Ward
Alie Ward
Technically Speaking: An Intel Podcast
iHeartPodcasts
Radiolab
WNYC Studios
Making Sense with Sam Harris
Sam Harris

You Might Also Like

Wild Wellness with Jess
Jess Reid
The Pound of Cure Weight Loss Podcast
Matthew Weiner, MD and Zoe Schroeder, RD
The Girl Next Door Podcast
Kelsey Wharton and Erica Ladd
The Mom Hour
Mom Hour Media